NPCE (NeuroPace) Payments of Debt: $0.00 Mil (TTM As of Mar. 2026)


NPCE NeuroPace Inc NPCE
68 GF Score
Price $15.76
GF Value $11.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is NeuroPace Payments of Debt?

NeuroPace NPCE -0.82% 68 Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates NPCE with a GF Score™ of 68/100 and a GF Value™ of $11.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

NeuroPace's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

NeuroPace's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

NeuroPace Payments of Debt Related Terms

NeuroPace Payments of Debt Historical Data

* Premium members only.

The historical data trend for NeuroPace's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroPace Payments of Debt Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial -4.09 0.00 0.00 0.00 -60.51

NeuroPace Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NPCE
68GF Score
NeuroPace Inc NPCE
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroPace Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
NeuroPace (NPCE) has a Payments of Debt of $0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on NeuroPace and its competitors.
Is NeuroPace's Payments of Debt too high?
NeuroPace's current Payments of Debt is $0.00 Mil. Overall, NeuroPace has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's Payments of Debt compare to CLPT and CTKB?
NeuroPace's Payments of Debt of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on NeuroPace and its competitors. NeuroPace's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $15.76 — trading 38.1% above its estimated fair value. The current Payments of Debt is $0.00 Mil. NeuroPace's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For NeuroPace (NPCE), the current Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroPace (NPCE) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued. The current stock price of $15.76 is trading 38.1% above its estimated GF Value™ of $11.41. GuruFocus considers NeuroPace to be Significantly Overvalued.

Key valuation signals for NPCE:

  • Payments of Debt: $0.00 Mil
  • GF Value™: $11.41 vs. price of $15.76 (38.1% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroPace Business Description

Address 455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
68GF Score

Get the complete analysis for NPCE

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.76
Price
$11.41
GF Value